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Summary
Background There are poorly documented variations in the journey a skin cancer
patient will follow from diagnosis to treatment in the European Union.
Objectives To investigate the possible difficulties or obstacles that a person with a
skin malignancy in the European Union may have to overcome in order to
receive adequate medical screening and care for his ⁄her condition. In addition,
we wished to explore differences in European health systems, which may lead to
health inequalities and health inequities within Europe.
Methods Ten European countries took part in this investigation (in alphabetical
order): Finland, Germany, Greece, Italy, Malta, Poland, Romania, Spain, the
Netherlands and the U.K. The individual participants undertook local and national
enquiries within their own country and completed a questionnaire.
Results This exercise has identified important differences in the management of a
skin cancer patient, reflecting major disparities in health care between European
countries.
Conclusions Further investigation of health disparities and efforts to address health
inequalities should lead to improvements in European health care quality and
reduction in morbidity from skin cancer.
Skin cancer, with its steadily increasing incidence in caucasian
populations, is emerging as an important health issue.1,2 The
number of patients with newly diagnosed skin cancer has risen
dramatically in the past decades, leading to a growing demand
for efficient health care services to examine suspicious skin lesions
and to treat patients. According to the World Health Organization
(WHO), the burden of disease due to ultraviolet radiation-related
skin cancer for all ages is 310 903 disability adjusted life years for
the European WHO region.3 Most skin cancers are of keratinocyte
origin, also referred to as nonmelanoma skin cancers (NMSCs),
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comprising basal cell carcinoma (BCC) and squamous cell carci-
noma (SCC), with some authors including in this group also pre-
cancerous skin lesions called actinic keratosis (AK).
Although mortality from NMSC is low,4 skin cancers
can induce substantial functional and cosmetic morbidity (espe-
cially within the head and neck area) and because of their high
prevalence they represent a considerable economic burden to
national health care systems (NHSs).4–7 Cutaneous malignant
melanomas (CMMs) represent only 5% of total skin cancers,
but are responsible for the majority of skin cancer deaths with
a disproportionate loss of life in young and middle-aged indi-
viduals.8 CMM is now the second most common cancer in indi-
viduals aged 15–34 years in the U.K. and the commonest cause
of a cancer-related death in young women.9 This relatively
young age distribution for CMM, with on average 20 years of
life lost for each melanoma death,8 emphasizes the importance
of prevention and early detection. If CMM is diagnosed early,
while still contained within the skin, surgical excision will be
curative. However, CMM has a great propensity for metastasis
and metastatic melanoma is resistant to most treatments, with
poor outcome at 5 years. Disparities on melanoma incidence
and survival have been reported in Europe.10,11 Compared with
Eastern Europe, the mortality ⁄ incidence ratios for CMM are low
in North-West Europe, despite high incidence rates. This
improved survival is likely to be related to earlier detection11 or
to the availability of more optimal treatment.
Health inequalities causing health inequity within Europe are
an important issue that is receiving growing attention. People
with a lower level of education and a lower socioeconomic class
are known to have a higher prevalence of most types of health
problems.12 Health care inequalities between the European coun-
tries will also lead to health inequity within the European Union
(EU). Health policy-making in the EU is firmly guided by the
principle of subsidiarity. The harmonization of national laws is
specifically excluded in Article 129 of the EU Treaty.12 This leads
to disparities in health care between the countries as a result of
social, financial and scientific differences. Less economically
developed and scientifically advanced European countries may
offer their citizens reduced access to health services for diagnosis
and treatment with less emphasis on health education and dis-
ease prevention. In contrast, more economically developed Euro-
pean countries may provide their patients with a variety of
benefits including improved health education, easier access to
health care, better diagnostic tools and more treatment options,
all of which will positively influence outcomes.
It is established that early detection and adequate treatment
are of paramount importance to the course and prognosis of a
patient with skin cancer, especially CMM. Consequently, less
medical provision for skin cancer or inadequate access to such
provision may cause not only discomfort and potential disfig-
urement, but can in some cases threaten a patient’s life.
Materials and methods
The EPIDERM project investigating skin cancers across Eur-
ope13 has identified and confirmed variations in skin cancer
incidence14,15 and treatment16 that exist between the partici-
pating centres. These variations may be attributed to inherent
differences in the populations under study (for example skin
colour, dietary variations, sun exposure practices etc.) but
may also reflect diversity between the NHSs in each country.
Our objective was to explore these variations using the EPI-
DERM consortium to investigate local policies regarding access
to health care, diagnosis and treatment for common skin can-
cers across Europe. We chose to focus on the skin cancer
patient and the ‘journey’ that he or she has to undertake in
order to receive a diagnosis and reach the most appropriate
treatment. All aspects were examined from the patient’s per-
spective as we were striving to discern all the potential con-
straints and obstacles a skin cancer patient might face, from
diagnosis to treatment.
Partners from the participating countries were asked to
provide information on the availability (number) of derma-
tologists, the referral pathway [direct access or referral via
the general practitioner (GP)], the waiting time for appoint-
ment (urgent and nonurgent; private and NHS), the need for
health insurance, the costs for the patient (private and NHS),
the possibility of reimbursement, the availability of different
treatment options, the costs (to the patient) of different treat-
ment options, the skin cancer follow-up policy, potential
obstacles for the skin cancer patient, within-country varia-
tions in practice and the ability (or not) of the patient to
buy skin cancer treatments over the counter and effectively
self-medicate.
The countries that were involved in this investigation were
the EPIDERM Partner countries (in alphabetical order): Fin-
land, Germany, Greece, Italy, Malta, Poland, Spain, the Neth-
erlands and the U.K. Romania also participated in the
investigation as we wanted to have information from an add-
itional Eastern European country. The individual participants
provided responses following local and national enquiries and
each holds complete responsibility for the given answers in
the different countries.
Results
Availability of dermatologists
In Table 1, the numbers of dermatologists and GPs are
depicted by country as well as the ratio of dermatologists to
population and the ratio of dermatologists to GPs.
The first discrepancy between countries was the method for
calculating these numbers and allocation of persons considered
to be contributory members of the dermatological workforce.
For example, in some countries the trainees (residents special-
izing in dermatology) see patients by themselves and are con-
sidered a part of the workforce, while in other countries
trainees are not allowed to consult by themselves and there-
fore their numbers are not included. In the U.K., the British
Association of Dermatologists has calculated that 191 trainees
in dermatology are equivalent to 40 full-time consultants and
thus 120 full-time equivalents (573 trainees) have been added
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to the 527 existing specialists to arrive at a total number of
647 dermatologists. Furthermore, in the U.K. among the
36 845 GPs there are 1400 GPs with a special interest (GPSIs)
in dermatology. These GPs will do at least one clinic per week
of only dermatology, some may do more, and thus they are
also contributing to the dermatological workforce. The density
of dermatologists differed considerably in the different Euro-
pean countries (Table 1). The dermatologists available per
100 000 population range from 1 (U.K.) to 11Æ4 (Greece),
and the ratio between dermatologists and GPs varies from 1:1
(Greece) to 1:57 (U.K.).
Ease of access to a dermatology consultation
Between-country variations relating to a consultation with a
dermatologist are presented in Table 2. Direct access to derma-
tology is only available in Greece and Poland, although in
Romania cases considered by the patient to be urgent also
have direct access without a referral. In all other countries, a
GP referral is needed before a patient can see a dermatologist
in the NHS. The NHS consultation prices in hospitals range
from no charge to the patient (Malta, Poland, Spain, U.K.) to
€27 in Central or University Hospitals in Finland. In Finland,
Germany, Greece, Poland and the Netherlands, health insur-
ance is obligatory, whereas in Italy, Malta, Spain and the U.K.
it is not required and in Romania it is not needed for emer-
gency cases.
The costs of a consultation in private dermatology also vary
significantly between countries. The most expensive private
consultations were reported in Italy where the price of a sim-
ple first consultation might reach €250 (Table 2).
There are also inequalities in waiting times between the dif-
ferent partner countries. In most cases when a patient is
referred by the GP as urgent (or in some countries presents
him ⁄herself as an emergency) the medical examination will
be scheduled within the same or the next day. In Spain there
is a 48–72 h waiting time with the use of teledermatology
and the U.K. has the longest waiting time of up to 2 weeks
for an urgent appointment. For a standard appointment wait-
ing time also varies. The longest waiting period is in Malta
where a patient might wait 2–4 months for a routine appoint-
ment and the shortest one is in Romania where a patient
referred by a GP, even if not classified as an emergency, is
seen on the same day. In Malta and the U.K., when a GP
requests that a patient is seen ‘soon’, there is an intermediate
waiting time: in Malta the patient is seen in 1–2 weeks instead
of waiting 2–4 months, whereas in the U.K. the maximum
waiting time is reduced from 13 weeks to 8 weeks.
In Greece patients can buy any medication, with the excep-
tion of strong painkillers ⁄morphine derivatives and antidepres-
sive drugs, without prescription from the pharmacy. In
Romania, patients can access some drugs without a prescription
if for an ‘urgent’ problem, whereas in all other countries a
medical prescription is necessary to obtain any drug from the
Table 1 Total number and ratio of dermatologists and general practitioners (GPs) per 100 000 population per country
Country
Number of
dermatologists
Dermatologists
per 100 000 population Number of GPs
Ratio of
dermatologists to GPs
Finland 192 3Æ6 3506 1:18
Germany 5314 6Æ5 43 103 1:8
Greece 1297 11Æ4 1300 1:1
Italy 5000 8Æ2 59 000 1:12
Malta 12 3 307 1:26
Poland 2500 6Æ5 15 000 1:6
Romania 591 2Æ7 11 000 1:19
Spain (NHS only) 1304 2Æ9 38 913 1:30
Netherlands 449 2Æ7 8921 1:20
U.K. 647 1 36 845 1:57
NHS, national health care system. Greece, Malta and U.K. have included specialist trainees. Other countries do not include their trainees
because trainees never see the patients independently. Malta has included one higher specialist trainee in dermatology. Greece has included
both residents and specialists (GPs and dermatologists), as in Greece trainees examine patients regularly. In the U.K. the total number of der-
matologists is calculated as the sum of whole-time equivalent consultant dermatologists. Senior specialist trainees will see patients indepen-
dently whereas junior trainees will tend to be supervised. The British Association of Dermatologists has calculated that 191 specialist trainees
are equivalent to 40 full-time consultants. Romania has included both residents and specialists in dermatology.
Sources: Finland Finnish Medical Association. Germany Number of actively working physicians in Germany 2010: http://www.bundesaerzte-
kammer.de/specialdownloads/Stat10Abb03.pdf (last accessed 13 April 2012). Number of inhabitants in Germany: approximately 82 million
(Statistisches Bundesamt): https://www.destatis.de/DE/ZahlenFakten/ZahlenFakten.html (last accessed 12 April 2012). Greece Hellenic Society
of Dermatology and Venereology, Hellenic Society of General Practitioners. Italy FIMMG, Italian Federation of General Practitioners. Romania
General population: 21 431 298 at 1 July 2010 (Centrul National de Statistica. Romania in Cifre): http://www.insse.ro/cms/files/publicatii/
Romania_in%20cifre%202011.pdf (last accessed 20 November 2011). Dermatologists: 591 at 31 December 2010 (Romanian Society of Der-
matology): http://www.srd.ro (last accessed 20 November 2011). GPs: 11 000 at 25 March 2011 (Ministry of Health – Romania): http://
www.ms.ro (last accessed 20 November 2011). Spain Ministry of Health, 2009. ‘Offers and needs of the medical specialists in Spain (2008–
2025)’. Netherlands NIVEL, Nederlands Instituut voor Onderzoek van de Gezondheidszorg: http://www.nivel.nl/ (last accessed 13 April 2012)
and personal communication with the Dutch Society of Dermatology and Venereology.
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pharmacy other than drugs listed as over-the-counter drugs,
which do not include drugs used for treatment of skin cancer.
There are also within-country variations in health care pro-
visions. In Germany, two distinct health care systems exist
with different management of patients, while there are also
differences between large and small cities and the countryside.
Greece, Italy and Spain also report differences across hospitals
and cities whereas the remaining countries report largely
homogeneous NHSs.
Availability and costs of diagnosis and skin cancer
treatments
The mainstay for skin cancer treatment is surgical excision. In all
countries patients may have a skin cancer surgically excised with-
out paying an additional fee for its removal because the NHS or
medical insurance policies will cover the actual costs (data not
shown). The exception is Greece where some national health in-
surances do not cover beforehand the surgical and histological
costs for excision of a primary tumour of the skin in an ambula-
tory setting and the patient has to pay prior to the operation and
afterwards apply for reimbursement. Classic surgical excisions
and use of grafts and flaps are available throughout Europe as
well as CMM-specific surgical procedures (wide local excision
and sentinel lymph node biopsy) although they are not always
performed by dermatologists; in some countries these are per-
formed by plastic or oncology surgeons. Furthermore, Mohs
micrographic surgery is not universally available: in Greece,
Malta, Poland and Romania (except for some research centres)
the Mohs technique is not performed (data not shown).
Diagnostic tools such as dermoscopy and mole mapping are
available throughout Europe with the exception of Malta and
Poland for mole mapping (Table 3). In most countries, dermos-
copy is included in the consultation fee or is offered free. In
Germany, a patient with public insurance pays €16 for dermos-
copy; in Romania s ⁄he pays €10 but only in private practice;
whereas in Italy patients pay €18 before the procedure, but if a
skin cancer is confirmed they are ultimately reimbursed. Mole
mapping is also free in several countries: in Greece, the price
depends on the centre (Papageorgiou Hospital €75); in Italy,
patients pay €36 which again is reimbursed if diagnosed with
skin cancer; in Germany, all patients with public insurance pay
€80; and in Romania, although free in the NHS, the high sum
of €585 is charged for mole mapping in private practice.
The nonsurgical treatments cryotherapy and topical 5% im-
iquimod cream (Aldara, MEDA, Brussels, Belgium) are avail-
able in all countries included in this survey, although the
prices paid by the patients vary. Other topical therapies such
as diclofenac gel 3% (Solaraze, Almirall, Barcelona, Spain),
5-fluorouracil cream (Efudix, MEDA, Brussels, Belgium) and
photodynamic therapy (PDT) are available in Europe, but not
in all countries. Furthermore, there is no charge to patients in
some countries while in others they must contribute to the
costs of these treatments. The actual (official) prices of the
drugs differ as well (Table 4), reflecting further variation in
the costs incurred by the different health systems.
The official indications for these topical skin cancer treat-
ments are broadly equivalent. For example, imiquimod is
licensed in all countries for AK and superficial BCC (sBCC),
whereas PDT cream (Metvix, Galderma, France) is licensed
for AK, sBCC, in situ SCC and usually for nodular BCC as well.
In Romania, PDT exists only as a research modality at limited
dermatological centres where it is used in clinical trials. In
Poland, PDT is not performed, whereas in Malta it is available
only in private practice.
Follow-up
Follow-up practices also vary between the participating coun-
tries and are summarized in Table 5. In some countries (Finland,
Spain) there are national guidelines for CMM follow-up, but not
for BCC or SCC. In others (Netherlands, Germany and U.K.) na-
tional guidelines exist for all three cancers. Yet other countries
(Italy and Malta) report adherence to the American or the U.K.
guidelines for CMM. In general, Breslow thickness is the most
important factor influencing CMM follow-up in all countries,
although the precise protocol varies. For BCC, no follow-up is
practised in some countries (Malta, Spain) and for SCC there are
many differences between the proposed schedule of follow-up
visits proposed in the different countries.
Discussion
This report has several limitations. Firstly, the data were col-
lected from the patient’s perspective from physicians practising
in the participating countries and not from the national health
care authorities. Without the exact prices for reimbursement of
the various treatments, we cannot address actual costs of skin
cancer to the different health systems. Secondly, we could
compare drug prices among the nonsurgical therapies, but the
reimbursement cost as well as the true cost of cryotherapy, the
most commonly used nonsurgical modality,16 were difficult to
obtain and could not be compared across Europe. Finally, we
did not investigate metastasis scenarios despite the importance
of these for patient survival, because in several countries
(including the U.K., Greece and the Netherlands) metastatic
melanoma is in the domain of the oncologists, making it
impractical to address this within the framework of this report.
Recently Patricia Garcia-Prieto Chevalier, a melanoma stage
IV patient and founder of the Melanoma Independent Com-
munity Advisory Board, stated in her talk in the European par-
liament that: ‘…many of the existing hurdles confronted by
cancer patients in Europe exist because we have simply forgotten
WHY… Efforts from politicians, pharmaceutical industry and
even doctors are focused on HOW, how to reduce the burden
on cancer costs, how to find blockbuster drugs faster and
bring them to the market quicker, how to enhance overall
survival no matter what... If patients are recognized at the cen-
tre of the debates and are actually communicated with, we
might all just remember WHY?’.
In an attempt to keep the patient centre stage, this report
has focused on the skin cancer ‘journey’ from the perspective
 2012 The Authors
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of the patient and has examined differences existing across
Europe that might hinder early diagnosis and optimal treat-
ment of skin cancer. This report is an attempt to examine skin
cancer care across Europe and it has revealed several important
variations despite the limitations stated above. These differ-
ences are of critical importance where they relate to the wait-
ing time for an expert skin consultation. Delayed diagnosis
may directly impact on outcome for those skin cancers where
the only curative treatment is early diagnosis and timely surgi-
cal excision. Also influential is the role of the GP in the man-
agement of skin cancers in many European countries. Where
the waiting time to be seen by a specialist is dependent on an
urgent referral by the GP (Finland, Germany, Italy, Malta,
Netherlands and U.K.), it becomes critically important that the
GP has had sufficient training to recognize skin lesions that
are suspicious of CMM or SCC. This requires a level of train-
ing that is not reliably achieved in most health services and
highlights an area of need. GPs are needed to triage referrals
in health care systems where there is a shortage of dermato-
logically trained specialists. In countries like the U.K. where
there are few dermatologists per head of population (U.K.:
one dermatologist per 100 000 population; one for every 57
GPs), it may be necessary to invest in dermatological training
for GPs. In the U.K. there are 1400 GPSIs in dermatology who
have received additional training to try and compensate for
this shortage in dermatologists. Despite this increased
resource, there is still perceived a need to improve the diag-
nostic accuracy of GP referrals via the ‘urgent’ pathway.
There is also considerable variability in the cost and avail-
ability of some skin cancer treatments across Europe. In some
European countries newer treatments such as PDT are either
very expensive for patients (Germany) or not available (Poland
and Malta). Similarly, Mohs micrographic surgery, which is
the gold standard for optimal treatment of some difficult cases
of primary and recurrent BCC and SCC, does not exist in some
European countries because of its expense. As predicted, treat-
ment availability and treatment costs are greatly influenced by
the financial prosperity of specific countries. This will inevita-
bly produce health inequities across Europe.
Follow-up of the different skin cancers similarly varies
between countries. It is assumed there will be survival benefit
to patients on a more intensive follow-up schedule or with
the use of more sophisticated diagnostic tests, but as yet no
comparative study has assessed the cost-effectiveness of the
different follow-up schedules.
In conclusion, this report highlights variations in skin can-
cer management across Europe. This provides a better insight
into health disparities, both in the accessibility of specialists
and in the provision and costs of treatment. A more detailed
study based on data taken directly from the respective NHSs is
now needed if we are to appreciate fully the variations
between countries and start the work that is needed to over-
come these health inequities. Such data will provide better
estimates of treatment-related costs and these, together with
cost-benefit analyses and an evidence base for treatment
choices, should ultimately result in improved strategies against
skin cancer.
What’s already known about this topic?
• There have been previous publications on health
inequalities within Europe as well as articles examining
diagnostic tools and therapeutic strategies for skin cancer
in major European countries.
What does this study add?
• This is the first multicentre attempt to collect compre-
hensive information on diagnosis, examination, treat-
ment and costs for a skin cancer patient from 10
European countries, together with the different strategies
and protocols followed in these countries.
Table 4 Differences between countries in official prices of topical drugs for skin cancer treatment
Country
5-fluorouracil
cream (Efudix)
5% imiquimod
cream (Aldara)
(one box with 12 sachets)
Diclofenac gel 3%
(Solaraze)
Methyl aminolaevulinate
cream (Metvix) (one tube: 2 g)
Finland N ⁄A €87Æ05 €177Æ76 ⁄100 g €336Æ76
Germany €54Æ74 €101Æ61 €72Æ49 ⁄40 g
€122Æ76 ⁄90 g
€404Æ58
Greece N ⁄A €62Æ96 N ⁄A €330Æ62
Italy Galenic form only €76Æ56 €36Æ72 ⁄25 g €387Æ27
Malta €32Æ87 €62Æ96 N ⁄A N ⁄A
Poland €25 €70 N ⁄A N ⁄A
Romania €27 €52 N ⁄A €561
Spain Galenic form only €112 N ⁄A €233
Netherlands €20Æ57 €59Æ99a N ⁄A €297Æ75
U.K. £32Æ73 ⁄40 g £48Æ34 £38Æ30 ⁄50 g
£76Æ60 ⁄100 g
£238Æ80
N ⁄A, not available. aIn the Netherlands Aldara is not sold as a box of 12 sachets. However, 12 sachets are often prescribed, as the treat-
ment is three times a week for 4 weeks (3 · 4 = 12).
 2012 The Authors
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